{"pmid":32361099,"pmcid":"PMC7194943","title":"The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19.","text":["The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19.","Med Hypotheses","Salem, Mohamed Labib","El-Hennawy, Dina","32361099"],"journal":"Med Hypotheses","authors":["Salem, Mohamed Labib","El-Hennawy, Dina"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361099","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.mehy.2020.109752","topics":["Treatment"],"weight":1,"_version_":1666138495535546370,"score":9.490897,"similar":[{"pmid":32437628,"title":"COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?","text":["COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?","Am J Respir Crit Care Med","Maes, Tania","Bracke, Ken","Brusselle, Guy G","32437628"],"journal":"Am J Respir Crit Care Med","authors":["Maes, Tania","Bracke, Ken","Brusselle, Guy G"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437628","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1164/rccm.202005-1651ED","keywords":["covid-19","sars-cov-2","asthma","inhaled corticosteroids"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667521393781112832,"score":41.036148},{"pmid":32471278,"title":"Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.","text":["Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.","At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses. COVID-19 pathology is characterized by extreme inflammation and amplified immune response with activation of a cytokine storm. A subsequent progression to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) can take place, which is often followed by death. The causes of these strong inflammatory responses in SARS-CoV-2 infection are still unknown. As uncontrolled pulmonary inflammation is likely the main cause of death in SARS-CoV-2 infection, anti-inflammatory therapeutic interventions are particularly important. Fenretinide N-(4-hydroxyphenyl) retinamide is a bioactive molecule characterized by poly-pharmacological properties and a low toxicity profile. Fenretinide is endowed with antitumor, anti-inflammatory, antiviral, and immunomodulating properties other than efficacy in obesity/diabetic pathologies. Its anti-inflammatory and antiviral activities, in particular, could likely have utility in multimodal therapies for the treatment of ALI/ARDS in COVID-19 patients. Moreover, fenretinide administration by pulmonary delivery systems could further increase its therapeutic value by carrying high drug concentrations to the lungs and triggering a rapid onset of activity. This is particularly important in SARS-CoV-2 infection, where only a narrow time window exists for therapeutic intervention.","Int J Mol Sci","Orienti, Isabella","Gentilomi, Giovanna Angela","Farruggia, Giovanna","32471278"],"abstract":["At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses. COVID-19 pathology is characterized by extreme inflammation and amplified immune response with activation of a cytokine storm. A subsequent progression to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) can take place, which is often followed by death. The causes of these strong inflammatory responses in SARS-CoV-2 infection are still unknown. As uncontrolled pulmonary inflammation is likely the main cause of death in SARS-CoV-2 infection, anti-inflammatory therapeutic interventions are particularly important. Fenretinide N-(4-hydroxyphenyl) retinamide is a bioactive molecule characterized by poly-pharmacological properties and a low toxicity profile. Fenretinide is endowed with antitumor, anti-inflammatory, antiviral, and immunomodulating properties other than efficacy in obesity/diabetic pathologies. Its anti-inflammatory and antiviral activities, in particular, could likely have utility in multimodal therapies for the treatment of ALI/ARDS in COVID-19 patients. Moreover, fenretinide administration by pulmonary delivery systems could further increase its therapeutic value by carrying high drug concentrations to the lungs and triggering a rapid onset of activity. This is particularly important in SARS-CoV-2 infection, where only a narrow time window exists for therapeutic intervention."],"journal":"Int J Mol Sci","authors":["Orienti, Isabella","Gentilomi, Giovanna Angela","Farruggia, Giovanna"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471278","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/ijms21113812","keywords":["covid-19","adjuvant treatment","anti-inflammatory","antiviral environment","fenretinide","pulmonary delivery"],"topics":["Treatment"],"weight":1,"_version_":1668255193274253313,"score":40.37534},{"pmid":32388476,"title":"Is copper beneficial for COVID-19 patients?","text":["Is copper beneficial for COVID-19 patients?","Copper (Cu) is an essential micronutrient for both pathogens and the hosts during viral infection. Cu is involved in the functions of critical immune cells such as T helper cells, B cells, neutrophils natural killer (NK) cells, and macrophages. These blood cells are involved in the killing of infectious microbes, in cell-mediated immunity and the production of specific antibodies against the pathogens. Cu-deficient humans show an exceptional susceptibility to infections due to the decreased number and function of these blood cells. Besides, Cu can kill several infectious viruses such as bronchitis virus, poliovirus, human immunodeficiency virus type 1(HIV-1), other enveloped or nonenveloped, single- or double-stranded DNA and RNA viruses. Moreover, Cu has the potent capacity of contact killing of several viruses, including SARS-CoV-2. Since the current outbreak of the COVID-19 continues to develop, and there is no vaccine or drugs are currently available, the critical option is now to make the immune system competent to fight against the SARS-CoV-2. Based on available data, we hypothesize that enrichment of plasma copper levels will boost both the innate and adaptive immunity in people. Moreover, owing to its potent antiviral activities, Cu may also act as a preventive and therapeutic regime against COVID-19.","Med Hypotheses","Raha, Syamal","Mallick, Rahul","Basak, Sanjay","Duttaroy, Asim K","32388476"],"abstract":["Copper (Cu) is an essential micronutrient for both pathogens and the hosts during viral infection. Cu is involved in the functions of critical immune cells such as T helper cells, B cells, neutrophils natural killer (NK) cells, and macrophages. These blood cells are involved in the killing of infectious microbes, in cell-mediated immunity and the production of specific antibodies against the pathogens. Cu-deficient humans show an exceptional susceptibility to infections due to the decreased number and function of these blood cells. Besides, Cu can kill several infectious viruses such as bronchitis virus, poliovirus, human immunodeficiency virus type 1(HIV-1), other enveloped or nonenveloped, single- or double-stranded DNA and RNA viruses. Moreover, Cu has the potent capacity of contact killing of several viruses, including SARS-CoV-2. Since the current outbreak of the COVID-19 continues to develop, and there is no vaccine or drugs are currently available, the critical option is now to make the immune system competent to fight against the SARS-CoV-2. Based on available data, we hypothesize that enrichment of plasma copper levels will boost both the innate and adaptive immunity in people. Moreover, owing to its potent antiviral activities, Cu may also act as a preventive and therapeutic regime against COVID-19."],"journal":"Med Hypotheses","authors":["Raha, Syamal","Mallick, Rahul","Basak, Sanjay","Duttaroy, Asim K"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388476","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.mehy.2020.109814","keywords":["blood cells","covid-19","contact killing","copper","coronavirus","cu-deficiency","cuonps","cupric chloride","immunity","ros","sars-cov-2","th1/th2 cells","viral infection"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666428892667183104,"score":40.36175}]}